Esperance starts EP-100 Phase I trial

09/13/2009 | Pharmaceutical Business Review Online

Esperance Pharmaceuticals has started enrolling and dosing patients in a trial of EP-100, a targeted membrane-disrupting peptide designed to locate and treat cancer cells. Preclinical studies of the drug candidate in mice showed it decreased tumors in breast, prostate, ovarian and endometrial cancer xenografts. PET imaging also showed the drug decreased tumor cells after treatment.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care